Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fred Hutchinson Cancer Center
Age
7–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 7 years or older
Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis.
Diagnosis of chronic GVHD according to the criteria of the diagnosis and scoring group of the NIH consensus conference (Patient must have at least one diagnostic manifestation of chronic GVHD or one distinctive manifestation with pathological confirmation of the diagnosis. Concurrent acute GVHD manifestations will be allowed as long as at least one classic chronic manifestation is present.)
Initiation of a new systemic treatment for chronic GVHD in the past 4 weeks or anticipated within the next 4 weeks. Systemic treatment is defined as any medication or intervention that has intended systemic effects, including extracorporeal photopheresis, regardless of prior lines of therapy or prior treatment with the agent(s). If a patient is restarting a treatment to which they were previously exposed, they must have been off of it for at least 4 weeks before restarting.
No evidence of persistent or progressive malignancy at the time of enrollment
Evaluation at the transplant center at the time of study enrollment, and agreement to be re-evaluated at the transplant center up to four subsequent times: at 3 months, 6 months, and 18 months after enrollment and once if another treatment is added for chronic GVHD.
Signed, informed consent
You may not be if
Inability to comply with study procedures
Complete resolution of chronic GVHD at the time of enrollment (patient must have some measurable chronic GVHD activity)
Clareo Health | Chronic GVHD Response Measures Validation
